Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tRF_G6 mimic is a synthetic RNA oligonucleotide designed to replicate the function of a specific tRNA-derived fragment (tRF) identified in *Ginkgo biloba*. It is being investigated as a novel therapeutic approach for asthma, specifically targeting the underlying process of airway remodeling. The drug works by restoring mitochondrial homeostasis and regulating mitophagy in airway structural cells, which are often dysfunctional in chronic respiratory conditions. Its primary mechanism involves the modulation of Prostate Transmembrane Protein, Androgen Induced 1 (PMEPA1), a target that plays a significant role in cellular structural integrity and mitochondrial health. By addressing these pathways, tRF_G6 mimic aims to reverse airway structural changes and improve therapeutic outcomes in asthma patients who are resistant to conventional treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tRF_G6 mimic.